Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.56 USD
Change Today +0.01 / 0.15%
Volume 577.1K
RGLS On Other Exchanges
As of 8:10 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

3545 John Hopkins Court

Suite 210

San Diego, CA 92121

United States

Phone: 858-202-6300


Regulus Therapeutics Inc., a biopharmaceutical company, focuses on discovering and developing first-in-class drugs that target microRNAs to treat a range of diseases. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. Regulus microMarkers In 2014, the company established Regulus microMarkers, a division focused on identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline, collaborators and strategic partners. Through its microRNA target identification and validation efforts, the company has developed proprietary technologies for microRNA profiling and analysis of human clinical samples such as tissue. Regulus microMarkers utilizes a clinically-validated, highly reproducible, proprietary technology platform to identify microRNAs as potential biomarkers for disease and the company controls key intellectual property and know-how related to the division. Development Candidates The company is in the process of developing single-stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of specific target microRNAs. The company incorporates proprietary chemical modifications to enhance drug properties, such as potency, stability and tissue distribution. The company refers to these chemically modified oligonucleotides as anti-miRs. Strategic Alliances/Collaborations In 2010, the company formed a strategic alliance with Sanofi to discover and develop microRNA therapeutics for fibrotic diseases. In 2012, the company expanded the alliance to include potential microRNA therapeutics in oncology. In 2012, the company formed a strategic alliance with AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases and oncology. Pursuant to this alliance, the company continues to work towards the identification of development candidates on its programs partnered with AstraZeneca, such as its program targeting microRNA 103/107, or miR-103/107 for the treatment of metabolic diseases and microRNA-19, or miR-19 in oncology, a target selected by AstraZeneca in 2012. In addition, AstraZeneca has a contractual right to select a third microRNA target. In August 2014, the company and Biogen Idec entered into a new collaboration and license agreement to collaborate on microRNA biomarkers for multiple sclerosis. Strategy The main elements of the company’s strategy are to build a meaningful clinical portfolio by advancing its clinical programs and rapidly advancing its preclinical programs into clinical development; focus its resources on developing drugs for oncology indications or orphan diseases where the development and commercialization activities are appropriate for its size and financial resources; selectively form strategic alliances to augment its expertise and accelerate development and commercialization; develop microRNA biomarkers to support its therapeutic product candidates; and maintain its scientific and intellectual leadership in the microRNA field. Research and Development In 2014, the company’s research and development expenses included $41.0 million. Intellectual Property The company has intellectual property position and substantial know-how relating to the development and commercialization of microRNA therapeutics, composed of: approximately 200 patents and patent applications that the company owns or has in-licensed from academic institutions and third parties including its founding companies, related to microRNA and microRNA drug products; and approximately 850 patents or patent applications exclusively licensed from its founding companies, related to RNA technologies, including patent and patent applications relating to chemical modification of oligonucleotides that are useful for microRNA therapeutics. The company’s portfolio of exclusively and jointly owned patent and patent applications is composed of approximately 130 U.S. and foreign patents and patent applications with claims to compositions-of-matter or methods related to its microRNA drug products and microRNA product platform. The company jointly owns approximately 10 of the patents and pending applications including patents claiming methods for treating liver cancer, including hepatocellular carcinoma, or HCC, using anti-miRs targeting miR-21 and a patent claiming methods for treating liver cancer, including hepatocellular carcinoma, using miR-34a mimic. History Regulus Therapeutics Inc. was founded in the state of Delaware in 2007.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGLS:US $6.56 USD +0.01

RGLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arbutus Biopharma Corp $6.12 USD -0.18
Benitec Biopharma Ltd A$0.47 AUD 0.00
Dicerna Pharmaceuticals Inc $8.24 USD -0.64
Galena Biopharma Inc $1.73 USD -0.04
Silence Therapeutics PLC 222.00 GBp -2.25
View Industry Companies

Industry Analysis


Industry Average

Valuation RGLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 25.1x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGULUS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at